Revenue Interest Financing Liability - Additional Information (Details) - USD ($) $ in Thousands					12 Months Ended
	Sep. 30, 2026	Nov. 28, 2023	Oct. 31, 2022	May 03, 2022	Sep. 30, 2029	Sep. 30, 2028	Sep. 30, 2027	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenue Interest Financing Liability [Line Items]
Investors right to receive royalties termination description								The investors’ right to receive royalties on net sales will terminate when the investors have aggregate payments equal to 200% of the Investment Amount. In addition, at any time after April 30, 2024, the Company has the right to make a cap payment equal to 200% of the Investment Amount less any royalties already paid, at which time the agreement will terminate.
Investors receipt description								If the investors have not received aggregate payments of at least 100% of the Investment Amount by December 31, 2028, and at least 200% of the Investment Amount by December 31, 2037, each a Minimum Amount, then the Company will be obligated to make a cash payment to the investors in an amount sufficient to gross the investors up to the applicable Minimum Amount.
Default obligation description								Upon the occurrence of an event of default taking place between April 1, 2025 and April 1, 2028, or after April 1, 2028, the Company is obligated to pay 1.30 times Investment Amount, 1.65 times Investment Amount, and 2.0 times investment amount, respectively, less any amounts the Company previously paid pursuant to the agreement.
Gross proceeds								$ 0	$ 0
Revenue interest financing liability, effective interest rate								9.67%
Transaction costs								$ 0	0
Revenue interest financing liability								377,371	353,038	$ 306,927
Interest expense with revenue interest finance liability								39,052	$ 48,738
Minimum Cash Requirement
Revenue Interest Financing Liability [Line Items]
Minimum Cash Covenant, Amount	$ 30,000
Minimum Cash Requirement (50%)
Revenue Interest Financing Liability [Line Items]
Minimum Cash Covenant, Percentage							50.00%
Minimum Cash Requirement (75%)
Revenue Interest Financing Liability [Line Items]
Minimum Cash Covenant, Percentage						75.00%
Minimum Cash Requirement (100%)
Revenue Interest Financing Liability [Line Items]
Minimum Cash Covenant, Percentage					100.00%
Revenue Interest Financing Agreement
Revenue Interest Financing Liability [Line Items]
Percentage of investor share of royalty in net sales				10.00%
Percentage of aggregate payments on investment amount to investors on net sales				200.00%
Revenue Interest Financing Agreement Upon Occurrence of Event of Default Prior to April 1, 2025
Revenue Interest Financing Liability [Line Items]
Percentage of aggregate payment on investment amount to investors				1.30%
Revenue Interest Financing Agreement Upon Occurrence of Event of Default between April 1, 2025, and April 1, 2028
Revenue Interest Financing Liability [Line Items]
Percentage of aggregate payment on investment amount to investors				1.65%
Revenue Interest Financing Agreement Upon Occurrence of Event of Default after April 1, 2028
Revenue Interest Financing Liability [Line Items]
Percentage of aggregate payments on investment amount to investors on net sales				2.00%
Initial Investors NQ, Sagard, and Hercules | Revenue Interest Financing Agreement
Revenue Interest Financing Liability [Line Items]
Funds received from initial closing				$ 100,000
Initial Investors NQ, Sagard, and Hercules | Revenue Interest Financing Agreement Funding Commitment On During the Fourth Quarter of 2023
Revenue Interest Financing Liability [Line Items]
Investors additional funding amount upon FDA approval of vonoprazan for treatment of erosive esophagitis		$ 160,000
Initial Investors And CO Finance L V S X X X V I I L L C And Hercules [Member] | Revenue Interest Financing Agreement
Revenue Interest Financing Liability [Line Items]
Additional funding available								$ 0
Initial Investors And CO Finance L V S X X X V I I L L C And Hercules [Member] | Joinder Agreement
Revenue Interest Financing Liability [Line Items]
Additional funding achievement of sales milestone			$ 25,000
Initial Investors And CO Finance L V S X X X V I I L L C And Hercules [Member] | Joinder Agreement Additional Funding Upon FDA Approval or During the Fourth Quarter of 2023
Revenue Interest Financing Liability [Line Items]
Investors additional funding amount upon FDA approval of vonoprazan for treatment of erosive esophagitis			$ 15,000
Maximum | Initial Investors NQ, Sagard, and Hercules | Revenue Interest Financing Agreement
Revenue Interest Financing Liability [Line Items]
Investors funding amount				$ 260,000
Minimum | Revenue Interest Financing Agreement Percentage on Investment Amount On December December 31, 2028
Revenue Interest Financing Liability [Line Items]
Percentage of aggregate payment on investment amount to investors				100.00%
Minimum | Revenue Interest Financing Agreement Percentage On Investment Amount by December 31, 2037
Revenue Interest Financing Liability [Line Items]
Percentage of aggregate payment on investment amount to investors				200.00%